

**Related links**[European Drug Report package main page](#)
[Statistical Bulletin](#)
[Country overviews](#)
[Perspectives on Drugs](#)**Keyword(s)**[alcohol](#) | [amphetamines](#) | [best practice](#) | [cannabis](#) | [chemistry](#) | [co-morbidity](#) | [cocaine](#) | [consumption rooms](#) | [crime](#) | [death](#) | [demand](#) | [drug-law offences](#) | [environmental indicators](#) | [epidemiology](#) | [evaluation](#) | [gender](#) | [hallucinogens](#) | [harm reduction](#) | [health effects](#) | [heroin](#) | [HIV](#) | [infectious diseases](#) | [injecting](#) | [key indicators](#) | [law](#) | [markets](#) | [methodology](#) | [new drugs](#) | [older people](#) | [opioids](#) | [overdose](#) | [policy](#) | [polydrug use](#) | [prevalence](#) | [prevention](#) | [price](#) | [prison](#) | [problem drug use](#) | [public expenditure](#) | [purity](#) | [recreational drugs](#) | [Reitox](#) | [research](#) | [risk behaviour](#) | [school/students](#) | [seizures](#) | [social exclusion](#) | [social reintegration](#) | [spice](#) | [statistics](#) | [strategies](#) | [substitution treatment](#) | [supply](#) | [synthetic stimulants](#) | [trafficking](#) | [treatment](#) | [trends](#) | [young people](#)**European Drug Report 2015: Trends and Developments**

EMCDDA, Lisbon, June 2015

Publication type: [European Drug Report: Trends and developments](#)**Summary:**

Changing dynamics in the heroin market, the latest implications of cannabis use and new features and dimensions of the stimulant and 'new drugs' scene are among the issues highlighted in the *European Drug Report 2015: Trends and Developments*. This year's annual review reflects on 20 years of monitoring and examines the global influences and local ramifications of Europe's ever-changing drugs problem.

**Download as ePub (4.0 MB)**[English](#)**Download as pdf (5.1Mb):**

Bulgarian (bg)	Spanish (es)	Czech (cs)
Danish (da)	German (de)	Estonian (et)
Greek (el)	English (en)	French (fr)
Italian (it)	Latvian (lv)	Lithuanian (lt)
Hungarian (hu)	Dutch (nl)	Polish (pl)
Portuguese (pt)	Romanian (ro)	Slovakian (sk)
Slovene (sl)	Finnish (fi)	Swedish (sv)
Croatian (hr)	Turkish (tr)	Norwegian (no)

Table of contents

- Preface
- Introductory note and acknowledgements
- Summary: Drug market dynamics in Europe: global influences and local differences
- Chapter 1: Drug supply and the market
- Chapter 2: Drug use and drug-related problems
- Chapter 3: Health and social responses to drug problems
- Annex: National data tables

**Pages:** 86**Price:** free**ISBN/ISSN:** 2314-9086**DOI:** 0.2810/084165**Catalogue number:**
TDAT15001ENC

Order this
publication from
the EU
Bookshop >>

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
[More contact options >>](#)

Quick links

[Annual report](#)
[Events](#)
[Press room](#)
[Vacancies](#)
[Partners](#)
[FAQ](#)
[Legal notice](#)

Follow us

[Twitter](#)
[Facebook](#)
[Flickr](#)
[YouTube](#)
[RSS](#)

[more >>](#)[Newsletter](#)[Site map](#)**Inside emcdda.europa.eu****Quick links**

[Action on new drugs](#)
[Contact](#)
[European Drug Report](#)
[Drug profiles](#)
[Key indicator gateway](#)
[Press room](#)
[Reitox network](#)
[Site map](#)
[Statistics and data on drugs in Europe](#)

Key publications

[Cannabis production and markets](#)
[Drug use, impaired driving and traffic accidents](#)
[ECDC and EMCDDA guidance on prevention and control of infectious diseases](#)
[EU drug markets report](#)
[European Drug Report: trends and developments](#)
[Harm reduction: evidence, impacts and challenges](#)
[Models of addiction](#)
[New psychoactive substances: annual implementation report](#)

Drug profiles

[Amphetamine](#)
[Barbiturates](#)
[Benzodiazepines](#)
[BZP and other piperazines](#)
[Cannabis](#)
[Cocaine and crack](#)
[Fentanyl](#)
[Hallucinogenic mushrooms](#)
[Heroin](#)
[Khat](#)
[Kratom](#)
[LSD](#)
[MDMA \('Ecstasy'\)](#)
[Methamphetamine](#)
[Salvia divinorum](#)
[Synthetic cannabinoids and 'Spice'](#)
[Synthetic cathinones](#)
[Synthetic cocaine derivatives](#)
[Volatile substances](#)

Data and visualisations

Data and statistics
[European Drug Data](#)
[Key data sheets](#)

Data visualisations
[Characteristics of frequent cannabis users](#)
[Drug use prevalence in Europe maps](#)
[Health and social responses in Europe](#)
[Treatment demand data for heroin in Europe](#)
[Wastewater analysis data visualisation](#)

Interactive features
[A sample of mass media campaigns in Europe](#)
[Geographical extent of regional drug strategies](#)
[Legal innovations in controlling new psychoactive substances](#)
[Methamphetamine global timeline](#)
[Synthetic cannabinoids: demystifying the chemistry](#)
[Synthetic cathinones: demystifying the chemistry](#)
[Synthetic drugs and precursors: understanding the connections](#)

Countries

[!\[\]\(f60b7a900783ac3fd531bfd9c111be6d_img.jpg\) Austria](#)
[!\[\]\(fe5cf1978663f480c504f8fc2019fe62_img.jpg\) Belgium](#)
[!\[\]\(3251ba33ee7a8fbbf21e8e8207062a79_img.jpg\) Bulgaria](#)
[!\[\]\(c1a98665bacc172e098c6f37717f87e5_img.jpg\) Croatia](#)
[!\[\]\(2fb06e195b16ba50a8e26637755ef33a_img.jpg\) Cyprus](#)
[!\[\]\(2546c16c0747e72574fb436e811eacd9_img.jpg\) Czech Republic](#)
[!\[\]\(94b39f940a3d8689839f3645a30a2849_img.jpg\) Denmark](#)
[!\[\]\(122a83b86d367a589e4703df33e911ae_img.jpg\) Estonia](#)
[!\[\]\(b02ed3307e7c42333b17b115bd487829_img.jpg\) Finland](#)
[!\[\]\(e7c820afcaee4cc755dc52e6c3e42b2e_img.jpg\) France](#)
[!\[\]\(096b0179af04e78af4e4d6473abb3ad4_img.jpg\) Germany](#)
[!\[\]\(5ab85e5cb123e14094bd63b237891cb3_img.jpg\) Greece](#)
[!\[\]\(3b0a7f2b32ed80f044060acad2d38c8f_img.jpg\) Hungary](#)
[!\[\]\(4e03c5a6a5798a9ecfbf07f62e520b98_img.jpg\) Ireland](#)
[!\[\]\(17e6ae2aeabaffbe62197ce2d9fb98f3_img.jpg\) Italy](#)
[!\[\]\(95678770eee2b4f6f18e0cc765d0d981_img.jpg\) Latvia](#)
[!\[\]\(deba173566fb581ec2b263062b9a810f_img.jpg\) Lithuania](#)
[!\[\]\(1534a6e264401a4f3343ba6f7761b63b_img.jpg\) Luxembourg](#)
[!\[\]\(bfdb7f6ef09ee823543a39ca469287a5_img.jpg\) Malta](#)
[!\[\]\(52fa5f9518c3552da5d4d87cee706462_img.jpg\) Netherlands](#)
[!\[\]\(a73a8f7413671292d604a62fe8462696_img.jpg\) Norway](#)
[!\[\]\(0c8a8e93ba7f26ebe321f0a7b7542cea_img.jpg\) Poland](#)
[!\[\]\(2b6e6630ffd126ab0e936d9031bbdfcd_img.jpg\) Portugal](#)
[!\[\]\(f5fab23f8fc800259b6461be9ad9b571_img.jpg\) Romania](#)
[!\[\]\(ceacbb9ec23b531f229a21e6174e48cd_img.jpg\) Slovakia](#)
[!\[\]\(df18fb714365ed7e30d7c4913412f22e_img.jpg\) Slovenia](#)
[!\[\]\(877f55b5c237ac5c7aa2020b736c87e4_img.jpg\) Spain](#)
[!\[\]\(6db58538a0c9194f77cfd00eec6f534f_img.jpg\) Sweden](#)
[!\[\]\(5252643ab3383853f6c4a16b39899572_img.jpg\) Turkey](#)
[!\[\]\(9c9b021b78b0d50cf406fec100530ef2_img.jpg\) United Kingdom](#)